Free Trial
→ The Midwestern Disruptor Big Pharma Doesn’t Want You to Know About (From Compounding Quality) (Ad)tc pixel
NASDAQ:SNES

Senestech Q3 2026 Earnings Date & Estimates

Senestech logo
$0.65 +0.01 (+0.79%)
As of 10:47 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Senestech is estimated to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. The conference call is scheduled for 5:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
5:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Senestech in Q3 2026

Senestech is expected to post earnings of -$0.33 per share on revenue of $0.80 million. In the same quarter a year earlier Senestech reported -$0.28 per share on revenue of $0.69 million. Senestech last reported on August 5, 2026, posting -$0.35 per share and beating the -$0.37 consensus estimate. Senestech has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.33
Expected Revenue
$0.80 million
Prior-Year EPS
-$0.28
Prior-Year Revenue
$0.69 million
Expected Revenue Growth
+15.5%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.35 (Beat by +$0.02)
Last Quarter Revenue
$0.77 million
EPS Beat Rate
7 of last 8 quarters

Prepare for the Q3 2026 Call

Senestech Q3 2026 Earnings FAQ

Senestech (NASDAQ:SNES) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Senestech's Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 5:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Senestech to post earnings of -$0.33 per share for Q3 2026.

The consensus revenue estimate for Senestech is $0.80 million for Q3 2026.

Senestech Earnings Headlines

SenesTech Expands Third-Party E-commerce Distribution with Grove Collaborative, Bringing Evolve® Rodent Birth Control™ Products to Sustainability-Focused Consumers
September 23, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/senestech-expands-third-party-e-commerce-distribution-with-grove-collaborative-bringing-evolve-rodent-birth-control-products-to-sustainability-focused-consumers-302886918.html
SenesTech to Participate in the Lytham Partners Fall 2026 Investor Conference
September 17, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/senestech-to-participate-in-the-lytham-partners-fall-2026-investor-conference-302882578.html
The $42 Billion Breakthrough That Took 40 Years to Arrive
GLP-1, the compound behind Eli Lilly's Mounjaro, was discovered more than 40 years ago. It took four decades for that science to become a drug that generated 65 billion dollars in revenue last year and sent Eli Lilly shares up 323 percent since approval. One little known Midwestern company is working to shorten that timeline. It uses advanced technology to help biotech startups bring new treatments to market faster.tc pixel
October 14 at 1:00 AM  |  Compounding Quality (Ad)
Swampscott Municipal Integrated Pest Management Program Achieves 43% Reduction in Rodent Activity with Evolve® Rat
August 31, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/swampscott-municipal-integrated-pest-management-program-achieves-43-reduction-in-rodent-activity-with-evolve-rat-302864436.html
SenesTech Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 27, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/senestech-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-302861052.html
SenesTech to Participate in the Lytham Partners 2026 Consumer & Technology Investor Summit on August 18, 2026
August 17, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/senestech-to-participate-in-the-lytham-partners-2026-consumer--technology-investor-summit-on-august-18-2026-302853101.html
See More Senestech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Senestech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Senestech and other key companies, straight to your email.

About Senestech

Senestech (NASDAQ:SNES) is a life sciences company focused on developing fertility-control technologies for managing pest populations. The company’s approach is designed to reduce the reproduction of rodents rather than relying solely on traditional lethal control methods.

SenesTech’s primary product is ContraPest, a liquid bait formulated to target the fertility of both male and female rats. The product is intended for use in settings such as commercial facilities, urban areas, agricultural operations and other locations where rodent populations can create health, safety or economic risks. The company has also developed Evolve Soft Bait, a rodent fertility-control product designed for use in certain pest-management applications.

Founded in 2004 and headquartered in Flagstaff, Arizona, SenesTech has focused on commercializing its technology in the United States while pursuing broader applications and distribution opportunities. Its products are developed for professional pest-control markets and other customers seeking alternatives or complements to conventional rodent-control methods.

View Senestech Profile
Earnings Tools